Active substanceIndapamide + PerindoprilIndapamide + Perindopril
Similar drugsTo uncover
  • Ko-Parnavel
    pills inwards 
    ATOLL, LLC     Russia
  • Ko Perineva®
    pills inwards 
    KRKA-RUS, LLC     Russia
  • Co-Benefit®
    pills inwards 
    KRKA-RUS, LLC     Russia
  • Noliprel®
    pills inwards 
  • Noliprel® A
    pills inwards 
  • Noliprel® A B-forte
    pills inwards 
  • Noliprel® A forte
    pills inwards 
  • Noliprel® forte
    pills inwards 
  • Perindapam®
    pills inwards 
    Sandoz d.     Slovenia
  • Perindid
    pills inwards 
  • GEDEON RICHTER, OJSC     Hungary
  • Dosage form: & nbsppills
    Composition:

    1 tablet contains:

    active substances: perindopril erbumine (perindopril tert-butylamine) 2 mg, which corresponds to 1.669 mg perindopril base, indapamide 0.625 mg;

    Excipients: silicon dioxide colloidal anhydrous, microcrystalline cellulose, lactose monohydrate, magnesium stearate.

    Description:

    Oblong white tablets with a risk on both sides.

    Pharmacotherapeutic group:antihypertensive agent combined (diuretic + ACE inhibitor)
    ATX: & nbsp

    C.09.B.A.04   Perindopril in combination with diuretics

    Pharmacodynamics:

    Noliprel® is a combined preparation containing perindopril (angiotensin-converting enzyme inhibitor) and indapamide (diuretic from the group of sulfonamide derivatives). The pharmacological properties of Noliprel® combine the individual properties of each of the components.

    The combination of perindopril and indapamide increases the effect of each of them.

    Perindopril

    Perindopril is an inhibitor of the enzyme converting angiotensin I to angiotensin II (an ACE inhibitor). An angiotensin-converting enzyme, or kinase, is an exopeptidase that carries out both the conversion of angiotensin I into a vasoconstrictor substance, angiotensin II, and the destruction of bradykinin having a vasodilating action to an inactive heptapeptide.

    As a result, perindopril:

    - reduces the secretion of aldosterone;

    - on the principle of negative feedback increases the activity of renin in the blood plasma;

    - with prolonged use reduces the overall peripheral vascular resistance, which is mainly due to the action on the vessels in the muscles and kidneys.

    These effects are not accompanied by a delay in salts and fluid or the development of reflex tachycardia.

    Perindopril normalizes the work of the myocardium, reducing preload and postnagruzku.

    When studying hemodynamic parameters in patients with chronic heart failure, it was revealed:

    - decrease of filling pressure in the left and right ventricles of the heart;

    - decrease in total peripheral resistance of blood vessels;

    - increased cardiac output and increased cardiac index;

    - increased peripheral muscle blood flow.

    Indapamide

    Indapamide belongs to the group of sulfonamides - by pharmacological properties it is close to thiazide diuretics. Indapamide inhibits the reabsorption of sodium ions in the cortical segment of the Henle loop, which leads to an increase in the release of kidney ions of sodium, chlorine and, to a lesser extent, potassium and magnesium ions, thereby increasing diuresis, and lowering blood pressure (BP).

    Hypotensive effect

    Noliprel®

    Noliprel ® has a dose-dependent hypotensive effect on both diastolic and systolic blood pressure (BP) in the "standing" and "lying" positions.The antihypertensive effect of the drug is maintained for 24 hours. The therapeutic effect occurs less than 1 month after the start of therapy and is not accompanied by tachycardia. Termination of treatment does not cause withdrawal syndrome. A synergistic hypotensive effect of perindopril and indapamide compared with monotherapy with these drugs was noted.

    Noliprel® reduces the degree of left ventricular hypertrophy, improves the elasticity of the arteries, reduces overall peripheral vascular resistance, does not affect lipid metabolism (total cholesterol, high-density lipoprotein cholesterol (HDL), and low-density lipoprotein (LDL) cholesterol, triglycerides).

    The effect of Noliprel® on cardiovascular morbidity and mortality has not been studied.

    In the study PICXEL The effect of the combination of perindopril and indapamide on left ventricular hypertrophy (LVH) was compared with enalapril. The severity of LVH was assessed by echocardiography.

    After randomization, patients with hypertension and LVH (LVMI-more than 120 g / m for men and more than 100 g / m for women) received perindopril 2 mg + indapamide 0.625 mg or enalapril 10 mg once daily for a year. To achieve control of blood pressure, the doses of the drugs were increased: perindopril - up to 8 mg and indapamide - up to 2.5 mg, and enalapril - up to 40 mg once a day. Only 34% of patients continued to receive perindopril 2 mg + indapamide 0.625 mg (in the enalapril group, 20% of patients continued to take the drug at a dose of 10 mg).

    At the end of therapy, a more significant decrease in LVMI was noted in the perindopril / indapamide group (-10.1 g / m2) compared with the indapamide group (-1.1 g / m2). The difference in the degree of decrease in this index between the groups was -8.3 g / m2 (95% CI (-11.5, -5.0), p <0.0001).

    In the group of patients who received combined therapy with perindopril and indapamide, compared with the enalapril group, a more pronounced hypotensive effect was noted. The difference in the degree of BP reduction among the groups in the general population of patients was -5.8 mm Hg. Art. (95% CI (-7.9, -3.7), p <0.0001) for systolic blood pressure, and -2.3 mm Hg. Art. (95% CI (-3.6, -0.9), p = 0.0004) for diastolic blood pressure.

    Perindopril

    Perindopril is effective in the treatment of arterial hypertension of any severity. The antihypertensive effect of the drug reaches a maximum in 4-6 hours after a single dose and lasts 24 hours.24 hours after taking the drug, a residual (about 80%) residual ACE inhibition is observed.

    Perindopril has an antihypertensive effect in patients with both low and normal renin activity in blood plasma.

    Perindopril has vasodilating effect, contributes to the restoration of elasticity and large arteries of the vascular wall structure of small arteries and reduces left ventricular hypertrophy.

    The concomitant use of thiazide diuretics increases the severity of antihypertensive action. In addition, the combination of an ACE inhibitor and a thiazide diuretic also leads to a reduction in the risk of hypokalemia with diuretics.

    Indapamide

    Indapamide in the form of monotherapy has antihypertensive effect, which lasts 24 hours. Antihypertensive effect is manifested when the drug is used in doses that have a minimal diuretic effect. The antihypertensive effect of indapamide is associated with an improvement in the elastic properties of large arteries, a reduction in overall peripheral vascular resistance. Indapamide reduces left ventricular hypertrophy.

    Thiazide and thiazide-like diuretics at a certain dose reach a plateau of therapeutic effect, while the incidence of side effects continues to increase with a further increase in the dose of the drug. Therefore, do not increase the dose of the drug, if the recommended dose is not achieved therapeutic effect.

    Indapamide does not affect the content of lipids in the blood plasma:

    - triglycerides, cholesterol, LLNV, HDL;

    - for carbohydrate metabolism (including in patients with concomitant diabetes mellitus).

    Pharmacokinetics:

    Noliprel®

    The combined use of perindopril and indapamide does not alter their pharmacokinetic characteristics as compared with the separate administration of these drugs.

    Perindopril

    Ingestion perindopril quickly absorbed. The maximum concentration in the blood plasma is reached 1 hour after ingestion. The half-life (T1/2) of the drug from the blood plasma is 1 hour. Perindopril does not possess pharmacological activity. Approximately 27% of the total amount of perindopril ingested enters the bloodstream as an active metabolite of perindoprilate.In addition to perindoprilata, another 5 metabolites are formed that do not have pharmacological activity. The maximum concentration of perindoprilat in the blood plasma is reached 3-4 hours after ingestion. Eating slows the conversion of perindopril to perindoprilat, thus affecting bioavailability. Therefore, the drug should be taken once a day, in the morning, before eating.

    There is a linear dependence of the concentration of perindopril in the blood plasma from its dose. The volume of distribution of free perindoprilata is approximately 0.2 l / kg. The association of perindoprilata with plasma proteins, mainly with ACE, depends on the concentration of perindopril and is about 20%.

    Perindoprilat is excreted from the body by the kidneys. "Effective" T1/2 free fraction is about 17 hours, so the equilibrium state is reached within 4 days.

    The excretion of perindoprilat is delayed in old age, as well as in patients with cardiac and renal insufficiency.

    The dialytic clearance of perindoprilat is 70 ml / min.

    The pharmacokinetics of perindopril has been altered in patients with cirrhosis of the liver: its hepatic clearance is reduced by a factor of 2.Nevertheless, the amount of perindoprilat formed does not decrease, which does not require dose adjustment (see the sections "Dosage and Administration" and "Special instructions").

    Indapamide

    Indapamide is rapidly and completely absorbed from the gastrointestinal tract. The maximum concentration of the drug in the blood plasma is observed 1 hour after ingestion.

    Relationship with blood plasma proteins - 79%.

    T1/2 is 14-24 hours (on average, 18 hours). The repeated use of the drug does not lead to its cumulation in the body. It is excreted mainly by the kidneys (70% of the administered dose) and through the intestine (22%) in the form of inactive metabolites. The pharmacokinetics of the drug does not change in patients with renal insufficiency.

    Indications:

    Essential arterial hypertension.

    Contraindications:

    Perindopril

    - Hypersensitivity to perindopril and other ACE inhibitors;

    - angioedema (Quincke's edema) in the anamnesis (including against the background of taking other ACE inhibitors);

    - hereditary / idiopathic angioedema;

    - Pregnancy (see section "Pregnancy and breastfeeding".);

    - the period of breastfeeding (see the section "Pregnancy and the period of breastfeeding").

    Indapamide

    - Hypersensitivity to indapamide or other sulfonamides;

    - marked renal failure (creatinine clearance (CK) less than 30 ml / min);

    - severe hepatic impairment (including encephalopathy);

    - hypokalemia;

    - simultaneous use with antiarrhythmic drugs that can cause arrhythmia of the "pirouette" type (see section "Interaction with other drugs");

    - the period of breastfeeding (see the section "Pregnancy and the period of breastfeeding").

    Noliprel®

    - Hypersensitivity to the excipients included in the preparation;

    - joint intake of the drug with potassium-sparing diuretics, potassium and lithium preparations, and in patients with elevated levels of potassium in blood plasma;

    - presence of lactase deficiency, galactosemia or glucose-galactose malabsorption syndrome;

    - simultaneous reception of drugs that extend the interval QT;

    - Due to a lack of sufficient clinical experience, Noliprel® should not be used in patients on hemodialysis;

    - Patients with untreated chronic heart failure in the stage of decompensation;

    - age under 18 years (efficiency and safety not established).

    Carefully:

    Systemic connective tissue disease (including systemic lupus erythematosus, scleroderma), immunosuppressants (risk of neutropenia, agranulocytosis) therapy, inhibition of bone marrow hematopoiesis, decreased blood volume (diuretics, salt-free diet, vomiting, diarrhea), angina pectoris, cerebrovascular disease , renovascular hypertension, diabetes, chronic heart failure (IV functional class classification NYHA), hyperuricemia (especially accompanied by gout and urate nephrolithiasis), lability of blood pressure, elderly age; hemodialysis using high-permeability membranes (for example, AN69®) or desensitization before apheresis procedure low density lipoprotein (LDL); condition after kidney transplantation; stenosis of the aortic valve / hypertrophic cardiomyopathy (see also sections "Special instructions" and "Interaction with other medicinal products").

    Pregnancy and lactation:

    Pregnancy

    Noliprel® is contraindicated in pregnancy (see. Section "Contraindications"). Noliprel® should not be used in the first trimester of pregnancy.When planning a pregnancy or when it occurs while taking the drug should immediately stop taking and prescribe another antihypertensive therapy. Appropriate controlled trials of ACE inhibitors in pregnant women have not been conducted. The available limited data on the effect of the drug in the first trimester of pregnancy indicate that the drug did not lead to malformations associated with fetotoxicity.

    It is known that prolonged exposure to ACE inhibitors on the fetus in the II and III trimesters of pregnancy can lead to disruption of its development (decreased kidney function, oligohydramnion, delayed ossification of the skull bones) and development of complications in the newborn (such as kidney failure, arterial hypotension, hyperkalemia) .

    Long-term use of thiazide diuretics in the III trimester of pregnancy can cause hypovolemia in the mother and a decrease in uteroplacental blood flow, which leads to fetoplacental ischemia and delayed fetal development. In rare cases, against the background of diuretics shortly before delivery, neonates develop hypoglycemia and thrombocytopenia.

    If the patient received Noliprel® during the second or third trimester of pregnancy, it is recommended to perform fetal ultrasound for. assessment of the state of the skull bones and kidney function.

    Breastfeeding period

    Noliprel® is contraindicated in the period of breastfeeding.

    It is not known whether the perindopril in breast milk.

    Indapamide penetrates into breast milk. Taking thiazide diuretics causes a decrease in the amount of breast milk or suppression of lactation. The child may develop hypersensitivity to derivatives of sulfonamides, hypokalemia and "nuclear" jaundice.

    Since the use of perindopril and indapamide during lactation can cause severe complications in the infant, it is necessary to evaluate the importance of therapy for the mother and decide whether to stop breastfeeding or stop taking these medications.

    Dosing and Administration:

    Inside, preferably in the morning, before meals, 1 tablet of Noliprel ® once a day. If the desired antihypertensive effect was not achieved within a month after the start of therapy, the dose of the drug can be doubled to a dosage of 4 mg + 1.25 mg (available under the trade name Noliprel® forte).

    Elderly patients (see section "Special instructions")

    Before you start taking the drug, you need to assess the functional activity of the kidneys and the concentration of potassium in the blood plasma. At the beginning of therapy, the dose of the drug is selected, given the degree of BP reduction, especially in the case of dehydration and loss of electrolytes.

    Therapy should be started with 1 tablet of Noliprel ® once a day.

    Renal insufficiency (see section "Special instructions")

    The drug is contraindicated in patients with severe renal failure (CC less than 30 ml / min). For patients with moderate renal insufficiency (CK 30-60 ml / min), the maximum dose of Noliprel ® is 1 tablet per day.

    In some patients with AH without previous obvious impairment of kidney function, the laboratory signs of functional

    renal failure. In this case, treatment should be discontinued. In the future, you can resume combination therapy, using low doses of drugs, or use drugs in monotherapy.

    Renal failure often occurs in patients with severe heart failure or an initial impairment of kidney function, including with renal artery stenosis.

    Patients with SC, equal to or greater than 60 ml / min, do not need dose adjustment.On the background of therapy, it is necessary to control the level of creatinine and potassium in the blood plasma.

    Liver failure (see the sections "Contraindications", "Special instructions", "Pharmacokinetics")

    The drug is contraindicated in patients with severe hepatic impairment.

    With moderate hepatic insufficiency, dose adjustment is not required.

    Children and teens

    Noliprel® should not be given to children and adolescents under 18 years of age because of lack of data on efficacy and safety in patients of this age group.

    Side effects:

    Perindopril has an inhibitory effect on the "renin-angiotensin-aldosterone" system and reduces the loss of potassium by the kidneys while taking indapamide. In 2% patients on the background of the drug Noliprel ® develops hypokalemia (potassium level less than 3.4 mmol / l).

    The frequency of adverse reactions that may occur during therapy is given in the following gradation: very often (> 1/10); often (> 1/100, <1/10); infrequently (> 1/1000, <1/100); rarely (> 1/10000, <1/1000); very rarely (<1/10000); unspecified frequency (frequency can not be calculated from available data), including individual messages.

    From the side of the blood and lymphatic system

    Rarely: thrombocytopenia, leukopenia / neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia.

    In certain clinical situations (patients after kidney transplantation, patients on hemodialysis), ACE inhibitors can cause anemia (see section "Special instructions").

    From the central nervous system

    Often: paresthesia, headache, dizziness, asthenia.

    Infrequently: sleep disturbance, lability of mood.

    Rarely: confusion of consciousness.

    From the side of the organ of vision

    Often: visual impairment.

    From the side of the hearing organ

    Often: noise in ears.

    From the side of the cardiovascular system

    Infrequently: a marked decrease in blood pressure, including orthostatic hypotension.

    Rarely: heart rhythm disturbances, including bradycardia, ventricular tachycardia, atrial fibrillation, as well as angina and myocardial infarction, possibly due to an excessive reduction in blood pressure in patients at high risk (see section "Special instructions").

    From the respiratory system

    Often: against the background of the use of ACE inhibitors may occur a dry cough that persists for a long time during the intake of drugs of this group and disappears after their withdrawal. Dyspnea.

    Infrequently: bronchospasm.

    Rarely: eosinophilic pneumonia, rhinitis.

    From the digestive system

    Often: constipation, dry mouth, nausea, vomiting, abdominal pain, epigastric pain, impaired taste, decreased appetite, indigestion, diarrhea.

    Rarely: angioedema, intestinal edema, cholestatic jaundice.

    Rarely: pancreatitis

    Patients with hepatic insufficiency may develop hepatic encephalopathy.

    From the skin and subcutaneous fat

    Often: rash, skin rash, itching, maculopapular rash.

    Infrequently:

    - angioedema, edema of the face, lips, limbs, tongue mucous membranes, glottis and / or larynx; urticaria (see section "Special instructions");

    - reactions of hypersensitivity, mainly skin, in patients predisposed to asthmatic and allergic reactions, hemorrhagic vasculitis.

    In patients with acute disseminated lupus erythematosus, the course of the disease may worsen.

    Rarely: erythema multiforme, toxic epidermal necrolysis, Stephen-Jones syndrome.

    Cases of photosensitivity reactions are noted (see section "Special instructions").

    From the musculoskeletal system and connective tissue

    Often: muscle spasms.

    From the urinary system

    Infrequently: renal insufficiency.

    Rarely: acute renal failure.

    From the side of the reproductive system

    Infrequently: impotence.

    General disorders and symptoms

    Often: asthenia.

    Infrequently: sweating.

    Laboratory indicators:

    - hypokalemia, especially significant for patients at risk (see section "Special instructions");

    - hyponatremia and hypovolemia leading to dehydration and orthostatic hypotension;

    - increased levels of uric acid and glucose in the blood during the administration of the drug;

    - a small increase in the level of urea and creatinine in the blood plasma, which occurs after the abolition of therapy, more often in patients with renal artery stenosis, in the treatment of arterial hypertension with diuretics and in the case of renal failure;

    - hyperkalemia, often transient.

    Rarely: hypercalcemia.

    Overdose:

    Symptoms

    The most likely symptom of an overdose is a marked decrease in blood pressure, sometimes in combination with nausea, vomiting, convulsions, dizziness, drowsiness, confusion and oliguria, which can go to anuria (as a result of hypovolemia).Also, electrolyte disorders (hyponatremia, hypokalemia) may occur.

    Treatment

    Emergency measures are reduced to excretion from the body: gastric lavage and / or the appointment of activated charcoal, followed by restoration of the water-electrolyte balance.

    With a significant decrease in blood pressure, the patient should be transferred to the "lying" position on the back with raised legs, if necessary, correction of hypovolemia (for example, intravenous infusion of 0.9% sodium chloride solution). Perindoprilat, an active metabolite of perindopril, can be removed from the body by dialysis.

    Interaction:

    Perindopril, indapamide

    Unwanted combination of drugs

    - Lithium preparations: with simultaneous use of lithium drugs and ACE inhibitors, a reversible increase in the concentration of lithium in the blood plasma and the associated toxic effects may occur. The additional administration of thiazide diuretics may further increase the concentration of lithium and increase the risk of toxicity. The simultaneous use of a combination of perindopril and indapamide with lithium preparations is not recommended.In the case of such therapy, regular monitoring of lithium content in blood plasma (see section "Special instructions") is necessary.

    A combination of funds that requires special attention

    - Baclofen: possibly strengthening the hypotensive effect. It is necessary to monitor blood pressure and kidney function, if necessary, correction of the dose of antihypertensive drugs is required.

    - Non-steroidal anti-inflammatory drugs (NSAIDs), including high doses of acetylsalicylic acid (more than 3 g / day): the appointment of NSAIDs can lead to a decrease in diuretic, natriuretic and hypotensive effects. With a significant loss, fluid, as well as in elderly patients, acute renal failure may result (due to a decrease in glomerular filtration rate). Patients need to compensate for fluid loss and at the beginning of treatment carefully monitor kidney function.

    A combination of funds that requires attention

    - Tricyclic antidepressants, antipsychotics (antipsychotics): drugs of these classes enhance the antihypertensive effect and increase the risk of orthostatic hypotension (additive effect).

    - Glucocorticosteroids, tetracosactide: decreased hypotensive effect (fluid retention and sodium ions as a result of glucocorticosteroids).

    - Other antihypertensives: possibly strengthening the hypotensive effect.

    Perindopril

    Unwanted combination of drugs

    - Potassium-sparing diuretics (amiloride, spironolactone, triamterene both as monotherapy, and in combination) and potassium preparations: ACE inhibitors reduce the loss of potassium by kidneys, caused by a diuretic. Potassium-sparing diuretics (for example, spironolactone, triamterene, amiloride), potassium preparations and potassium-containing substitutes for edible salt can lead to a significant increase in potassium concentration in the serum, up to a lethal outcome. If the combined use of an ACE inhibitor and the above preparations is necessary (in the case of confirmed hypokalemia), caution should be exercised and regular monitoring of potassium concentration in the blood plasma and ECG parameters should be performed.

    A combination of funds that requires special attention

    - Hypoglycemic agents (insulin, sulfonylurea derivatives): the following effects were described for captopril and enalapril.ACE inhibitors can enhance the hypoglycemic effect of insulin and sulfonylureas in patients with diabetes mellitus. The development of hypoglycemia is very rare (due to an increase in glucose tolerance and a decrease in insulin requirements).

    A combination of funds that requires attention

    - Allopurinol, cytostatic and immunosuppressive agents, corticosteroids (for systemic use), and procainamide: simultaneous use with ACE inhibitors may be accompanied by an increased risk of leukopenia.

    - Means for general anesthesia: the combined use of ACE inhibitors and agents for general anesthesia can lead to an increased hypotensive effect.

    - Diuretics (thiazide and loop): the use of diuretics in high doses can lead to hypovolemia, and the addition of perindopril to hypotension.

    - Preparations of gold: nitrate-like reactions (facial hyperemia, nausea, vomiting, hypotension) were noted in patients receiving injections of gold (sodium aurothiomalate) when prescribing ACE inhibitors, including perindopril.

    Indapamide

    A combination of funds that requires special attention

    - Medicines that can cause arrhythmia such as "pirouette": Because of the risk of developing hypokalemia, caution should be exercised when using indapamide together with drugs capable of causing piruet-type arrhythmias, for example, with antiarrhythmic drugs (quinidine, hydroquinidine, disopyramide, amiodarone, dofetilide, ibutilide, brethulium, sotalol); some neuroleptics (chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoroperazine); benzamides (amisulpride, sulpiride, sultopride, tiapride); butyrophenones (droperidol, haloperidol); other neuroleptics (pimozide); other drugs, such as bepridil, cisapride, difemanyl, erythromycin in / in, halofantrine, misolastine, moxifloxacin, pentamidine, sparfloxacin, wincamine in / in, methadone, astemizole, terfenadine. Avoid the development of hypokalemia and, if necessary, carry out its correction; monitor the interval QT.

    - Medicines that can cause hypokalemia ": amphotericin B (IV), gluco- and mineralocorticosteroids (for systemic administration), tetracosactide, laxatives, stimulating intestinal motility: increased risk of hypokalemia (additive effect). It is necessary to control the level of potassium in the blood plasma, if necessary, its correction. Particular attention should be given to patients who simultaneously receive cardiac glycosides. Use laxatives that do not stimulate intestinal motility.

    - Cardiac glycosides: hypokalemia increases the toxic effect of cardiac glycosides. With the simultaneous use of indapamide and cardiac glycosides, it is necessary to monitor the level of potassium in the blood plasma and the parameters of the ECG and, if necessary, adjust the therapy.

    A combination of funds that requires attention

    - Metformin: functional renal failure, which can occur with the use of diuretics, especially loop, while concomitant administration of metformin increases the risk of developing lactic acidosis. Do not use metformin, if the level of creatinine in the blood plasma exceeds 15 mg / L (135 μmol / L) in men and 12 mg / L (110 μmol / L) in women.

    - Iodine-containing contrast agents: dehydration of the body against the background of taking diuretic drugs increases the risk of acute renal failure,especially when using high doses of iodine-containing contrast agents. Before using iodine-containing contrast agents, patients should compensate for fluid loss.

    - Salts of calcium: with simultaneous administration, it is possible to develop hypercalcemia due to decreased excretion of calcium ions by the kidneys.

    - Cyclosporine: it is possible to increase the level of creatinine in the blood plasma without changing the concentration of circulating cyclosporine, even with a normal content of liquid and sodium ions.

    Special instructions:

    Perindopril, indapamide

    The use of Noliprel ® is not accompanied by a significant reduction in the incidence of side effects, with the exception of hypokalemia, compared with perindopril and indapamide in the lowest dose permitted for use (see section "Side effect"). At the beginning of therapy with two antihypertensive drugs, which the patient did not receive earlier, one can not exclude the increased risk of idiosyncrasy. Careful observation of the patient makes it possible to minimize this risk.

    Lithium preparations

    The simultaneous use of a combination of perindopril and indapamide with lithium preparations is not recommended (see.section "Interaction with other drugs").

    Impaired renal function

    Therapy is contraindicated in patients with severe renal failure (CC less than 30 ml / min). In some patients with AH without previous obvious impairment of renal function against the background of therapy, laboratory signs of functional renal failure may appear. In this case, treatment should be discontinued. In the future, you can resume combination therapy, using low doses of drugs, or use drugs in monotherapy.

    Such patients need regular monitoring of potassium and serum creatinine level - 2 weeks after the beginning of therapy and then every 2 months. Renal failure often occurs in patients with severe heart failure or an initial impairment of kidney function, including stenosis of one or two renal arteries.

    As a rule, the use of perindopril and indapamide is not recommended for patients with bilateral stenosis of the renal arteries or stenosis of a single functioning kidney.

    Arterial hypotension and disturbance of water-electrolyte balance

    Hyponatremia is associated with a risk of sudden development of arterial hypotension (especially in patients with stenosis of one or two renal arteries). Therefore, when observing patients dynamically, attention should be paid to possible symptoms of dehydration and a decrease in the level of electrolytes in the blood plasma, for example, after diarrhea or vomiting. Such patients need regular monitoring of the level of plasma electrolytes.

    With severe arterial hypotension, intravenous administration of 0.9% sodium chloride solution may be required.

    Transient arterial hypotension is not a contraindication for the continuation of therapy. After recovering the volume of circulating blood and blood pressure, you can resume therapy using low doses of drugs, or use drugs in monotherapy.

    Potassium level

    The combined use of perindopril and indapamide does not prevent the development of hypokalemia, especially in patients with diabetes mellitus or renal insufficiency. As in the case of combined use of antihypertensive drugs and diuretic, regular monitoring of the potassium level in the blood plasma is necessary.

    Excipients

    It should be borne in mind that the composition of excipients of the drug includes lactose monohydrate. Do not prescribe Noliprel® to patients with hereditary intolerance to galactose, lactase deficiency, and glucose-galactose malabsorption.

    Perindopril

    Neutropenia / agranulocytosis

    The risk of developing neutropenia against the background of the administration of ACE inhibitors is dose-dependent and depends on the drug taken and the presence of concomitant diseases. Neutropenia rarely occurs in patients without concomitant diseases, but the risk increases in patients with impaired renal function, especially against the background of systemic connective tissue diseases (including systemic lupus erythematosus, scleroderma).

    After the withdrawal of ACE inhibitors, neutropenia signs pass independently.

    With extreme caution should be applied perindopril in patients with diffuse connective tissue diseases, with the use of immunosuppressive drugs, allopurinol or procainamide and with simultaneous exposure to these factors, especially in patients with initial renal impairment.Some patients experienced severe infectious lesions, in some cases, resistant to intensive antibiotic therapy. When appointing perindopril to such patients - it is recommended to periodically monitor the number of leukocytes in the blood. Patients should inform the doctor of any signs of infectious diseases (eg, angina, fever).

    Hypersensitivity / angioedema (angioedema)

    When taking ACE inhibitors, including perindopril, in rare cases, development of angioedema of the face, limbs, lips, tongue, glottis and / or larynx can be observed. If symptoms appear, the perindopril should be stopped immediately, and the patient should be observed until the signs of edema disappear completely. If the edema affects only the face and lips, then its manifestations usually pass independently, although antihistamines may be used to treat its symptoms.

    Angioedema, accompanied by swelling of the larynx, can lead to death. Swelling of the tongue, glottis or larynx can lead to airway obstruction.When such symptoms occur, immediately enter subcutaneously epinephrine (epinephrine) in a dilution of 1: 1000 (0.3 or 0.5 ml) and / or provide airway patency.

    Patients with a history of Quincke edema not associated with the administration of ACE inhibitors may be at increased risk of developing it with the use of drugs of this group (see the section "Contraindications"),

    In rare cases, against the background of therapy with ACE inhibitors, angioedema develops in the intestine. In this case, patients have abdominal pain as an isolated symptom or in combination with nausea and vomiting, in some cases without a prior angioedema and at a normal level of C-1 esterase. The diagnosis is established using computed tomography of the abdominal region, ultrasound or at the time of surgery. Symptoms disappear after stopping the intake of ACE inhibitors. In patients with abdominal pain receiving ACE inhibitors, the differential diagnosis should take into account the possibility of developing angioedema edema of the intestine.

    Anaphylactoid reactions during desensitization

    There are separate reports on the development of long-term, life-threatening anaphylactoid reactions in patients receiving ACE inhibitors during desensitizing therapy with the poison of Hymenoptera insects (bees, wasps). ACE inhibitors should be used with caution in allergic patients who undergo desensitization procedures. The appointment of an ACE inhibitor should be avoided for patients receiving immunotherapy with venom of Hymenoptera. However, the anaphylactoid reaction can be avoided by temporarily lifting the ACE inhibitor at least 24 hours before the procedure.

    Anaphylactoid reactions during apheresis of LDL

    In rare cases in patients receiving ACE inhibitors, life-threatening anaphylactoid reactions may develop during low-density lipoprotein (LDL) apheresis using dextran sulfate. To prevent anaphylactoid reaction, therapy with an ACE inhibitor should be temporarily discontinued before each apheresis procedure.

    Hemodialysis

    In patients receiving ACE inhibitors, anaphylactoid reactions were noted in hemodialysis using high-flow membranes (eg AN69®).Therefore, it is desirable to use a different type of membrane or to use an antihypertensive drug of another pharmacotherapeutic group.

    Potassium-sparing diuretics and potassium preparations

    As a rule, the combined use of perindopril and potassium-sparing diuretics, as well as potassium and potassium-containing substitutes for edible salt is not recommended (see section "Interaction with other drugs").

    Cough

    Against the background of therapy with an ACE inhibitor, dry cough may occur. Cough persists for a long time against the background of taking this group's drugs and disappears after their withdrawal. When a dry cough occurs in a patient, one should keep in mind the possible connection of this symptom with the administration of an ACE inhibitor. If the attending physician believes that therapy with an ACE inhibitor is necessary for the patient, the drug may be continued.

    Children and teens

    Noliprel® should not be given to children and adolescents under the age of 18 due to a lack of data on the efficacy and safety of perindopril in the form of monotherapy or as part of combination therapy in patients of this age group.

    The risk of arterial hypotension and / or renal failure (in patients with heart failure, a violation of water-electrolyte balance, etc.)

    In some pathological states, a significant activation of the renin-angiotensin-aldosterone system can occur, especially with severe hypovolemia and a decrease in the level of plasma electrolytes (against a background of a salt-free diet or long-term diuretics), in patients with initially low blood pressure, stenosis of one or two renal arteries, chronic heart failure or cirrhosis of the liver with the presence of edema and ascites.

    The use of an ACE inhibitor causes blockade of this system and therefore can be accompanied by a sharp decrease in blood pressure and / or an increase in the level of creatinine in the blood plasma, indicating the development of functional renal failure. These phenomena are more often observed with the first dose of the drug or during the first two weeks of therapy. Sometimes these conditions develop rapidly in other periods of therapy. In such cases, when the therapy is resumed, it is recommended to use the drug in a lower dose and then gradually increase the dose.

    Elderly patients

    Before you start taking the drug, you need to assess the functional activity of the kidneys and the concentration of potassium in the blood plasma.At the beginning of therapy, the dose of the drug is selected, given the degree of BP reduction, especially in the case of dehydration and loss of electrolytes. Such measures allow to avoid a sharp decrease in blood pressure.

    Atherosclerosis

    The risk of hypotension exists in all patients but particular care should be taken using the drug in patients with ischemic heart disease and cerebrovascular insufficiency. In such patients, treatment should begin with low doses.

    Patients with Renovascular Hypertension

    The method of treating reninvascular hypertension is revascularization. Nevertheless, the use of ACE inhibitors has a beneficial effect in patients who are waiting for surgery, and in the case when it is impossible to perform such an operation.

    Treatment with Noliprel® for patients with diagnosed or suspected renal artery stenosis should begin with a low dose of the drug in a hospital setting, monitoring the kidney function and the concentration of potassium in the blood plasma. In some patients, functional renal failure may develop, which disappears when the drug is withdrawn.

    Other risk groups

    In patients with chronic heart failure (stage IV) and patients with insulin-dependent diabetes mellitus (the risk of spontaneous increase in potassium concentration), treatment should begin with a low dose of the drug (half a pill) and under constant medical supervision.

    Patients with arterial hypertension and coronary heart disease should not stop taking beta-blockers: ACE inhibitors should be used together with beta-blockers.

    Patients with diabetes mellitus

    When prescribing a drug for patients with diabetes mellitus receiving hypoglycemic agents for ingestion or insulin, during the first month of therapy, the blood glucose level must be carefully monitored.

    Ethnic differences

    Perindopril, like other ACE inhibitors, obviously has a less pronounced hypotensive effect in patients of the Negroid race compared with representatives of other races. Perhaps this difference is due to the fact that patients with arterial hypertension of the Negroid race are more likely to have low renin activity.

    Surgery / General Anesthesia

    The use of ACE inhibitors in patients undergoing surgery with the use of general anesthesia can lead to a marked decrease in blood pressure, especially with the use of general anesthetic agents that have an antihypertensive effect.

    It is recommended to stop the use of long-acting ACE inhibitors, including perindopril, 12 hours before the surgery.

    Aortic stenosis / mitral stenosis / Hypertrophic cardiomyopathy

    ACE inhibitors should be administered with caution to patients with left ventricular outflow obstruction.

    Liver failure

    In rare cases, with the administration of ACE inhibitors occurs. cholestatic jaundice. With the progression of this syndrome, fulminant liver necrosis develops, sometimes with a fatal outcome. The mechanism of development of this syndrome is unclear. When jaundice or a significant increase in the activity of "liver" enzymes against the background of taking ACE inhibitors should stop taking the drug and see a doctor (see section "Side effect").

    Anemia

    Anemia can develop in patients after kidney transplantation or in people on hemodialysis.At the same time, the decrease in hemoglobin concentration is greater, the higher its initial value was. This effect, apparently, is not dose-dependent, but may be related to the mechanism of action of ACE inhibitors.

    Hyperkalemia

    Hyperkalemia can develop during treatment with ACE inhibitors, including perindopril. Risk factors for hyperkalemia are renal failure, decreased kidney function, advanced age, diabetes mellitus, certain concomitant conditions (dehydration, acute decompensation of heart failure, metabolic acidosis), concurrent administration of potassium-sparing diuretics (such as spironolactone, eplerenone, triamterene, amiloride), as well as preparations of potassium or potassium-containing substitutes for edible salt, as well as the use of other drugs that increase the level of potassium in the blood plasma (for example, heparin). The use of potassium, potassium-sparing diuretics, potassium-containing substitutes for edible salt can lead to a significant increase in potassium levels in the blood, especially in patients with reduced renal function. Hyperkalemia can lead to serious, sometimes fatal heart rhythm disturbances.If a combination of the above drugs is required, treatment should be carried out with caution, against a background of regular monitoring of potassium in the blood serum (see section "Interaction with other drugs").

    Indapamide

    With the appointment of thiazide and thiazide-like diuretics, patients with impaired hepatic function may develop hepatic encephalopathy. In this case, the taking of diuretics should be stopped immediately.

    Photosensitivity

    Against the background of taking thiazide and thiazide-like diuretics, cases of development of photosensitivity reactions were reported (see the "Side effect" section). In the case of developing photosensitivity reactions against the background of taking the drug should stop treatment. If it is necessary to continue therapy with diuretics, it is recommended to protect the skin from exposure to sunlight or artificial UV rays.

    Water-electrolyte balance

    Content of sodium ions in blood plasma

    Before the start of treatment it is necessary to determine the content of sodium ions in the blood plasma. Against the background of taking the drug should regularly monitor this figure.All diuretic drugs can cause hyponatremia, which sometimes leads to serious complications. Hyponatremia at the initial stage may not be accompanied by clinical symptoms, so regular laboratory monitoring is necessary. More frequent monitoring of sodium ions is indicated for patients with cirrhosis of the liver and elderly people (see the sections "Side effect" and "Overdose").

    The content of potassium ions in the blood plasma

    Therapy with thiazide and thiazide-like diuretics is associated with a risk of hypokalemia. It is necessary to avoid hypokalemia (less than 3.4 mmol / L) in the following categories of patients at high risk: elderly patients, depleted patients or receiving concomitant medication, patients with cirrhosis, peripheral edema or ascites, coronary heart disease, heart failure. Hypokalemia in these patients increases the toxic effect of cardiac glycosides and increases the risk of arrhythmias.

    Patients with an increased QT interval also belong to the high-risk group, but it does not matter whether this increase is due to congenital causes or effects of medications.

    Hypokalemia, like bradycardia, contributes to the development of severe cardiac arrhythmias, especially arrhythmias such as pirouettes, which can be fatal. In all cases described above, more regular monitoring of the potassium ion content in the blood plasma is necessary. The first measurement of the concentration of potassium ions should be carried out within the first week from the start of therapy.

    If hypokalemia is detected, appropriate treatment should be prescribed.

    The content of calcium ions in the blood plasma

    Thiazide and thiazide-like diuretics reduce the excretion of calcium ions by the kidneys, leading to a slight and temporary increase in the concentration of calcium in the blood plasma. Expressed hypercalcemia may be a consequence of previously not diagnosed hyperparathyroidism. Before the study of the function of the parathyroid gland, it is necessary to cancel the intake of diuretic drugs.

    The content of glucose in the blood plasma

    It is necessary to monitor the blood glucose level in patients with diabetes mellitus, especially in the presence of hypokalemia.

    Uric acid

    In patients with elevated uric acid levels in blood plasma, the frequency of gout attacks may increase with therapy.

    Diuretics and kidney function

    Thiazide and thiazide-like diuretics are effective only in patients with normal or slightly impaired renal function (creatinine levels in adults below 25 mg / L or 220 μmol / L in plasma in adults). In elderly patients, the clearance of creatinine is calculated taking into account age, body weight and sex.

    At the beginning of treatment with diuretics in patients due to hypovolemia and hyponatremia, there may be a temporary decrease in the glomerular filtration rate and an increase in the concentration of urea and creatinine in the blood plasma. This transient functional renal failure is not dangerous for patients with unchanged kidney function, however, in patients with renal insufficiency, its severity can increase.

    Athletes

    Indapamide can give a positive reaction during doping control.

    Effect on the ability to drive transp. cf. and fur:

    The action of substances that make up the drug Noliprel®, does not lead to a disturbance of psychomotor reactions. However, in some patients, in response to a decrease in blood pressure, various individual reactions may develop,especially at the beginning of therapy or when adding other antihypertensive agents to the therapy. In this case, the ability to drive a car or other mechanisms can be reduced.

    Form release / dosage:

    Tablets, 2 mg + 0.625 mg.

    Packaging:

    For 14 or 30 tablets per blister (PVC / Al). The blister is placed in a protective sachet (polyester / aluminum / polyethylene) containing a desiccant-silica gel in a plastic coat with a cardboard lid. One blister packed in a sachet with instructions for medical use is placed in a cardboard pack.

    When packaging and packaging at the Russian company LLC "Serdiks"

    30 tablets per blister (PVC / Al). The blister is placed in a protective sachet (polyester / aluminum / polyethylene) containing a desiccant-silica gel in a plastic coat with a cardboard lid. One blister packed in a sachet with instructions for medical use is placed in a cardboard pack.

    Storage conditions:

    Special storage conditions are not required.

    The drug in the blister should be used within 2 months after the opening of the sachet.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Not apply at the expiration date indicated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N015714 / 01
    Date of registration:29.05.2009
    The owner of the registration certificate:Servier LaboratoriesServier Laboratories France
    Manufacturer: & nbsp
    Representation: & nbspServier Laboratories Servier Laboratories France
    Information update date: & nbsp19.10.2015
    Illustrated instructions
      Instructions
      Up